|
FOR IMMEDIATE
RELEASE
Contact:
communications@nof.org
Following is a Statement by the
National Osteoporosis Foundation on the
U.S. Food and Drug Administration’s
Approval of Actonel® for Broader Use in
Men with Osteoporosis
August 14, 2006 –
Osteoporosis is a serious, widespread
and growing public health threat
affecting both men and women,
according to the National Osteoporosis
Foundation (NOF). NOF welcomes any new
FDA approved treatment option, such as Actonel®, that will help
patients address this all too prevalent
disease. NOF estimates 44 million
American women and men age 50 and older
are at risk of breaking a bone due to
osteoporosis and low bone mass.
About NOF:
Established in 1984, the National
Osteoporosis Foundation is the nation’s
leading voluntary health organization
solely dedicated to osteoporosis and
bone health. Our mission is to prevent
osteoporosis, to promote lifelong bone
health, to help improve the lives of
those affected by osteoporosis and
related fractures, and to find a cure.
# # #
Back to
the Press Release Index |
